Biofrontera Inc. Files Routine 8-K, Updates Corporate Info

TL;DR

**Biofrontera Inc. filed a routine 8-K, no major news, just corporate info.**

AI Summary

Biofrontera Inc. filed an 8-K on February 5, 2024, to disclose general corporate information, including its incorporation in Delaware and its business address in Woburn, Massachusetts. This filing, under Regulation FD Disclosure, primarily serves to update administrative details and confirm its common stock, with a par value of $0.001 per share, is registered on an exchange. For investors, this filing is a routine administrative update and does not contain new financial or operational news that would significantly impact the stock price, but it confirms the company's continued compliance with SEC reporting requirements.

Why It Matters

This filing is a standard administrative update, confirming Biofrontera Inc.'s corporate structure and compliance, which is important for maintaining investor confidence in the company's regulatory adherence.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not contain any information that would introduce new risks or change the company's operational or financial outlook.

Analyst Insight

A smart investor would recognize this as a routine administrative filing with no immediate impact on the company's valuation or operational prospects, thus requiring no specific action based solely on this document.

Key Numbers

• $0.001 — Par Value per Share (The par value of Biofrontera Inc.'s common stock.)

Key Players & Entities

• Biofrontera Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Biofrontera Inc.
• Woburn, Massachusetts (company) — location of Biofrontera Inc.'s principal executive offices
• $0.001 (dollar_amount) — par value per share of common stock

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 43KB
• ex99-1.htm (EX-99.1) — 15KB
• 0001493152-24-004964.txt ( ) — 285KB
• bfri-20240205.xsd (EX-101.SCH) — 4KB
• bfri-20240205_def.xml (EX-101.DEF) — 27KB
• bfri-20240205_lab.xml (EX-101.LAB) — 37KB
• bfri-20240205_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 7KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On February 5, 2024, Biofrontera Inc. (the "Company") issued a press release announcing the U.S. Food and Drug Administration (FDA) has completed its filing review and has determined that Biofrontera's application to increase the maximally approved dosage from one to three tubes of Ameluz per treatment is sufficiently complete to permit a substantive review, a copy of which is attached here as Exhibit 99.1. The information in Item 7.01 of this Current Report is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. Item 9.01 Financial 99.1 Press release dated February 5, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. February 5, 2024 (Date) Biofrontera Inc. (Registrant) By: /s/ E. Fred Leffler III E. Fred Leffler III Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR